Cargando…
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
Autores principales: | Mascarenhas, J, Kosiorek, H, Prchal, J, Yacoub, A, Berenzon, D, Baer, MR, Ritchie, E, Silver, RT, Kessler, C, Winton, E, Finazzi, MC, Rambaldi, A, Vannucchi, AM, Leibowitz, D, Rondelli, D, Arcasoy, MO, Catchatourian, R, Vadakara, J, Rosti, V, Hexner, E, Kremyanskaya, M, Sandy, L, Tripodi, J, Najfeld, V, Farnoud, N, Salama, ME, Weinberg, RS, Rampal, R, Goldberg, JD, Mesa, R, Dueck, AC, Hoffman, R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884668/ https://www.ncbi.nlm.nih.gov/pubmed/31363161 http://dx.doi.org/10.1038/s41375-019-0524-7 |
Ejemplares similares
-
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
por: Mascarenhas, John, et al.
Publicado: (2022) -
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
por: De Stefano, V, et al.
Publicado: (2016) -
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
por: Finazzi, Guido, et al.
Publicado: (2018) -
P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
por: Gupta, V., et al.
Publicado: (2022) -
Human splanchnic amino-acid metabolism
por: Neis, Evelien P. J. G., et al.
Publicado: (2016)